Tolga Tanguler - 27 Feb 2026 Form 4 Insider Report for ALNYLAM PHARMACEUTICALS, INC. (ALNY)

Reporting relationship: EVP, Chief Commercial Officer
Issuer ticker: ALNY
Reported as of: 27 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Mar 2026, 16:09:17 UTC
Prior SEC filing: 17 Feb 2026
Next SEC filing: 04 Mar 2026
Source filing: View source filing
Reporting owner signature: By: Brett Budzinski, Attorney-in-Fact For: Tolga Tanguler

Key filing fact

Tolga Tanguler filed Form 4 for ALNYLAM PHARMACEUTICALS, INC. (ALNY) on 02 Mar 2026.

Key facts

This page summarizes Tolga Tanguler's Form 4 filing for ALNYLAM PHARMACEUTICALS, INC. (ALNY).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Mar 2026, 16:09.

Change

Previous filing in this sequence was filed on 17 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001849458 Primary reporting owner

Tanguler Tolga

Relationship: EVP, Chief Commercial Officer
Address: 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE
Signature: By: Brett Budzinski, Attorney-in-Fact For: Tolga Tanguler
Signature date: 02 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALNY transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +1,666
Change %: +5.2%
Price: $0.000000
Shares after: 33,435
Date: 27 Feb 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALNY transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -1,666
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 27 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,666
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock.

Footnote F2

On February 27, 2023, the reporting person was granted 5,000 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2026, the third and final tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4.

Footnote F3

The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date.